Efficacy of different pharmacological therapies for diffuse cutaneous systemic sclerosis: a systematic review and network meta-analysis - PubMed
5 hours ago
- #Network Meta-Analysis
- #Systemic Sclerosis
- #Pharmacological Therapies
- Network meta-analysis comparing pharmacological therapies for diffuse cutaneous systemic sclerosis (dcSSc).
- Rituximab most effective for reducing Modified Rodnan Skin Score (MRSS), followed by cyclophosphamide and belimumab.
- Belimumab and cyclophosphamide top interventions for improving forced vital capacity (FVC).
- Methotrexate most effective for enhancing diffusing capacity of the lung for carbon monoxide (DLCO).
- Belimumab and cyclophosphamide significantly lower Health Assessment Questionnaire (HAQ) scores.
- B-cell-targeted therapies like rituximab and belimumab excel in reducing MRSS and HAQ scores.
- Conventional immunosuppressants such as cyclophosphamide and methotrexate better for pulmonary function improvement.
- Tailoring treatment strategies based on organ involvement extent and severity is recommended.